Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-26
2011-04-26
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S322500
Reexamination Certificate
active
07932282
ABSTRACT:
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof:The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease, in particular pain such as inflammatory pain, neuropathic pain or visceral pain.
REFERENCES:
patent: 2005/0026916 (2005-02-01), Shum et al.
patent: 2008/0009541 (2008-01-01), Chambers et al.
patent: 5024287 (1975-03-01), None
patent: WO 99/29686 (1999-06-01), None
patent: WO 01/10799 (2001-02-01), None
patent: WO 2008/003697 (2008-01-01), None
Beswick Paul John
Dean David Kenneth
Gleave Robert James
Moses Andrew Peter
Walter Daryl Simon
Chu Yong
Fitch Duke M.
Glaxo Group Limited
Lemanowicz John
Shterengarts Samantha L
LandOfFree
Imidazolidine carboxamide derivatives as P2X7 modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazolidine carboxamide derivatives as P2X7 modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolidine carboxamide derivatives as P2X7 modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2665277